With the increased propensity to prescribe NAC to this group, the aim of the present study was to perform a systematic review and meta-analysis evaluating the role of pCR as a biomarker of survival in patients treated with NAC for HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.